Progressive CAG expansion in the brain of a novel R6/1-89Q mouse model of Huntington's disease with delayed phenotypic onset
- PMID: 17352932
- DOI: 10.1016/j.brainresbull.2006.10.015
Progressive CAG expansion in the brain of a novel R6/1-89Q mouse model of Huntington's disease with delayed phenotypic onset
Abstract
Transgenic models representing Huntington's disease (HD) have proved useful for understanding the cascade of molecular events leading to the disease. We report an initial characterisation of a novel transgenic mouse model derived from a spontaneous truncation event within the R6/1 transgene. The transgene is widely expressed, carries 89 CAG repeats and the animals exhibit a significantly milder neurological phenotype with delayed onset compared to R6/1. Moreover, we report evidence of progressive somatic CAG expansions in the brain starting at an early age before an overt phenotype has developed. This novel line shares a common genetic ancestry with R6/1, differing only in CAG repeat number, and therefore, provides an additional tool with which to examine early molecular and neurophysiological changes in HD.
Similar articles
-
Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice.Neurobiol Dis. 2009 Mar;33(3):331-41. doi: 10.1016/j.nbd.2008.11.015. Epub 2008 Dec 11. Neurobiol Dis. 2009. PMID: 19130884
-
CAG repeat lengths > or =335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse.Neurobiol Dis. 2009 Mar;33(3):315-30. doi: 10.1016/j.nbd.2008.10.009. Epub 2008 Nov 6. Neurobiol Dis. 2009. PMID: 19027857 Free PMC article.
-
Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1035-45. doi: 10.1098/rstb.1999.0456. Philos Trans R Soc Lond B Biol Sci. 1999. PMID: 10434303 Free PMC article.
-
Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.Acta Pharmacol Sin. 2006 Oct;27(10):1287-302. doi: 10.1111/j.1745-7254.2006.00410.x. Acta Pharmacol Sin. 2006. PMID: 17007735 Review.
-
Transgenic models of Huntington's disease.Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):963-9. doi: 10.1098/rstb.1999.0447. Philos Trans R Soc Lond B Biol Sci. 1999. PMID: 10434294 Free PMC article. Review.
Cited by
-
Mouse models of polyglutamine diseases: review and data table. Part I.Mol Neurobiol. 2012 Oct;46(2):393-429. doi: 10.1007/s12035-012-8315-4. Epub 2012 Sep 7. Mol Neurobiol. 2012. PMID: 22956270 Free PMC article. Review.
-
MSH3 polymorphisms and protein levels affect CAG repeat instability in Huntington's disease mice.PLoS Genet. 2013;9(2):e1003280. doi: 10.1371/journal.pgen.1003280. Epub 2013 Feb 28. PLoS Genet. 2013. PMID: 23468640 Free PMC article.
-
What is the Pathogenic CAG Expansion Length in Huntington's Disease?J Huntingtons Dis. 2021;10(1):175-202. doi: 10.3233/JHD-200445. J Huntingtons Dis. 2021. PMID: 33579866 Free PMC article. Review.
-
Huntington's disease: can mice lead the way to treatment?Neuron. 2011 Feb 10;69(3):423-35. doi: 10.1016/j.neuron.2010.12.035. Neuron. 2011. PMID: 21315254 Free PMC article. Review.
-
A Mechanism Leading to Changes in Copy Number Variations Affected by Transcriptional Level Might Be Involved in Evolution, Embryonic Development, Senescence, and Oncogenesis Mediated by Retrotransposons.Front Cell Dev Biol. 2021 Feb 11;9:618113. doi: 10.3389/fcell.2021.618113. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33644055 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases